Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Sarah, Doucette"'
Autor:
Daniel Breadner, David M. Hwang, Don Husereau, Parneet Cheema, Sarah Doucette, Peter M. Ellis, Shaqil Kassam, Natasha Leighl, Donna E. Maziak, Shamini Selvarajah, Brandon S. Sheffield, Rosalyn A. Juergens
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6017-6031 (2024)
Lung cancer is the leading cause of cancer-related deaths in Canada, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Timely access to comprehensive molecular profiling is critical for selecting biomarker-matched targeted
Externí odkaz:
https://doaj.org/article/f7cb34653c054cd781905d065bb3e78f
Autor:
Ravi Ramjeesingh, Prosanto Chaudhury, Vincent C. Tam, David Roberge, Howard J. Lim, Jennifer J. Knox, Jamil Asselah, Sarah Doucette, Nirlep Chhiber, Rachel Goodwin
Publikováno v:
Current Oncology, Vol 30, Iss 8, Pp 7132-7150 (2023)
Biliary tract cancers (BTC) are rare and aggressive tumors with poor prognosis. Radical surgery offers the best chance for cure; however, most patients present with unresectable disease, and among those receiving curative-intent surgery, recurrence r
Externí odkaz:
https://doaj.org/article/d675e5bc97264225a33cf325df2fb002
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 4222-4245 (2023)
The most common forms of B-cell malignancy, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), have seen a drastic shift in the treatment landscape over the last two decades with the introduction of targeted agents. Among them are Bru
Externí odkaz:
https://doaj.org/article/33e5bee18f334e2ea08c6d9a8c827f7f
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 1745-1759 (2023)
Marginal zone lymphomas (MZL) are a rare, heterogenous group of lymphomas, accounting for 5–17% of indolent non-Hodgkin lymphomas in the western world. They can be further divided into three subtypes: extranodal MZL, splenic MZL, and nodal MZL. The
Externí odkaz:
https://doaj.org/article/fe5aad47d91e40fb88f27f264e4ae5d9
Autor:
Vincent C. Tam, Ravi Ramjeesingh, Ronald Burkes, Eric M. Yoshida, Sarah Doucette, Howard J. Lim
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7072-7085 (2022)
Biliary tract cancer (BTC) is a group of rare and aggressive malignancies with a dismal prognosis. There is currently a significant lack in effective treatment options for BTC, with gemcitabine-cisplatin remaining the first-line standard of care trea
Externí odkaz:
https://doaj.org/article/c735cb9d60984c4192f079cf2016bd9c
Autor:
Rayan Kaedbey, Nicholas Forward, Laurie H. Sehn, Mona Shafey, Sarah Doucette, Christine I. Chen
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7122-7139 (2022)
Waldenström macroglobulinemia (WM) is a slowly progressing B-cell non-Hodgkin lymphoma characterized by monoclonal IgM gammopathy in the blood and infiltration of the bone marrow by clonal lymphoplasmacytic cells. As an incurable disease, the goals
Externí odkaz:
https://doaj.org/article/fa839af2ed4049deb6048093976a8a2c
Autor:
Anna V. Tinker, Alon D. Altman, Marcus Q. Bernardini, Prafull Ghatage, Lilian T. Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, Amit M. Oza
Publikováno v:
Current Oncology, Vol 29, Iss 6, Pp 4354-4369 (2022)
The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP
Externí odkaz:
https://doaj.org/article/fe8a21f7885c4aed92258cf4d73a89b6
Publikováno v:
Canadian Oncology Nursing Journal, Vol 31, Iss 0, Pp 1-11 (2021)
Bruton tyrosine kinase (BTK) inhibitors are an effective therapy for the treatment of chronic lymphocytic leukemia (CLL), particularly in patients who present with high-risk features. The first-in-class BTK inhibitor, ibrutinib, is generally tolerabl
Externí odkaz:
https://doaj.org/article/7372ed08c69d47abaaa648a267052a8a
Publikováno v:
Canadian Oncology Nursing Journal, Vol 31, Iss 0, Pp 1-13 (2021)
Les inhibiteurs de la tyrosine kinase de Bruton (BTK) traitent efficacement la leucémie lymphoïde chronique (LLC), particulièrement chez les patients à haut risque. L’ibrutinib, inhibiteur de la BTK pionnier, est généralement bien toléré. C
Externí odkaz:
https://doaj.org/article/dafa9a0aa2d3439f84cb94e7ed97003c
Autor:
Anthony Brade, Kevin Jao, Simon Yu, Parneet Cheema, Sarah Doucette, Anna Christofides, Devin Schellenberg
Publikováno v:
Current Oncology, Vol 28, Iss 3, Pp 1618-1629 (2021)
Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogenous group of patients with regards to patient fitness and tumour size and distribution, resulting in a wide range of treatment goals and therapy options. Curative-intent multimo
Externí odkaz:
https://doaj.org/article/db3f1f27baa04af5aa196de55eedb74e